Multi-center evaluation of antifungal time-kill methods

Journal of Infectious Disease Pharmacotherapy

Volumn 5, Issue 2, 2001, Pages 29-41

  Klepser, Michael E ^a   Lewis, Russell E ^b   Ernst, Erika J ^c   Rosemarie Petzold, C ^c   Bailey, Elaine M ^d   Burgess, David S ^e   Carver, Peggy L ^f   Lacy, Melinda K ^g   Mercier, Renee Claude ^h   Nicolau, David P ⁱ   Zhanel, George G ^j   Pfaller, Michael A ^c  

^a FERRIS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF KANSAS   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ HARTFORD HOSPITAL   (United States)

^j UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

Amphotericin; Antifungal; Candida; Fluconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CELL ISOLATION; CLASSIFICATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HUMAN; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; REPRODUCIBILITY;

EID: 18244378035     PISSN: 10687777     EISSN: None     Source Type: Journal    
DOI: 10.1300/J100v05n02_04     Document Type: Article

References (21)

1. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
2. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
3. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
4. Method of reliable determination of minimal lethal antibiotic concentrations
5. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
6. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species
7. In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole
8. Activity of fluconazole: Postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes
9. The postantibiotic effect of antifungal agents against common pathogenic yeasts
10. In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations
11. In vitro interaction between amphotericin B and azoles in Candida albicans
12. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
13. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
14. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time
15. Evaluation of endpoints for antifungal susceptibility determinations with LY303366
16. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model
17. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans
18. Growth medium effect on the antifungal activity of LY 303366
19. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
20. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp